Abstract
Pemphigus is a group of organ-specific, autoimmune, mucocutaneous blistering disorders with an established immunological basis. The goal of therapy in pemphigus is to eliminate or neutralize the pathogenic autoantibodies. As in other autoimmune diseases, early systemic therapy is important for control of the disease and for achieving sustained remissions. Because of the sparse number of controlled studies, the treatment of autoimmune bullous diseases remains controversial. In this article, we discuss the current therapeutical options in pemphigus with an emphasis on IVIg treatment and suggest guidelines for the use of IVIg in the treatment of pemphigus.
Similar content being viewed by others
References
Mimouni, D. and Anhalt, G. J. (2002), Dermatol Ther 15, 362–368.
Nousari, H. C. and Anhalt, G. J. (1999), Lancet 354, 667–672.
Anhalt, G. J. (1997), Adv Dermatol 12, 77–96.
Anhalt, G. J., Labib, R. S., Voorhees, J. J., Beals, T. F., and Diaz, L. A. (1982), N Engl J Med 306, 1189–1196.
Mimouni, D., Nousari, C. H., Cummins, D. L. Kouba, D. J., David, M., and Anhalt, G. J. (2003), J Am Acad Dermatol 49, 1059–1062.
Seidenbaum, M., David, M., and Sandbank, (1998), Int J Dermatol 27, 580–584.
Pasricha, J. S., Khaitan, B. K., Raman, R. S., and Chandra, M. (1995), Int J Dermatol 34, 875–882.
Mimouni, D., Anhalt, G. J., Cummins, D. L., Kouba, D. J., Thorne, J. E., and Nousari, H. C. (2003), Arch Dermatol 139, 739–742.
Tavadia, S. M., Mydlarski, P. R., Reis, M. D., et al. (2000), J Am Acad Dermatol 42, 628–632.
Cummins, D. L., Mimouni, D., Anhalt, G. J., and Nousari H. C. (2003), J Amer Acad Dermatol 49, 276–280.
Ioannides, D., Chrysomallis, F., and Bystryn, J. C. (2000), Arch Dermatol 136, 868–872.
Dupuy, A., Viguier, M., Bedane, C., et al. (2004), Arch Dermatol 140, 91–96.
Braun-Moscovici, Y. and Furst, D. E. (2003), Curr Opin Rheumatol 15, 237–245.
Shoenfeld, Y., Rauova, L., Gilburd, B., et al. (2002), Int Immunol 14, 1303–1311.
Krause, I., Wu, R., Sherer, Y., Patanik, M., Peter, J., and Shoenfeld, Y. (2002), Transfus Med 212, 133–139.
Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747–755.
Krause, I., Blank, M., and Shoenfeld, Y. (1998), J Clin Immunol 18, 52–60.
Evans, M. J., Suenaga, R., and Abdou, N.I. (1991), J Clin Immunopathol 11, 291–295.
Rossi, F. and Kazatchkine, M. D. (1989), J Immunol 143, 4104–4109.
Rossi, F., Jayne, D. R., Lockwood, C. M., and Kazatchkine, M. D. (1991), Clin Exp Immunol 83, 298–303.
Tandon, N., Jayne, D. R., McGregor, A. M., and Weetman, A. P. (1992), J Autoimmun 5, 557–570.
Lundkvist, I., van Doorn, P. A., Vermeulen, M., and Brand, A. (1993), Clin Immunol Immunopathol 67, 192–198.
Caccavo, D., Vaccaro, F., Ferri, G. M., Amoroso, A., and Bonomo, L. (1994), J Autoimmun 7, 537–548.
Shoenfeld, Y. and Krause, I. (2004), J Clin Immunol 24, 107–114.
Levy, Y., Sherer, Y., Ahmed A., et al. (1999), Lupus 8, 705–712.
Sami, N., Bhol, K. C., and Ahmed, A. R. (2003), Eur J Dermatol 13, 377–381.
Herzog, S., Schmidt, E., Goebeler, M., Brocker, E. B., and Zillikens, D. (2004), Acta Derm Venereol 84, 48–52.
Sami, N., Qureshi, A., Rucco, E., and Ahmed, A. R. (2002), Arch Dermatol 138, 1158–1162.
Ahmed, A.R. (2001), J Am Acad Dermatol 45, 679–690.
Bystryn, J. C., Jiao, D., and Nathow, S. (2002), J Am Acad Dermatol 47, 358–363.
Bewely, A. P. and Keefe, M. (1996), Br J Dermatol 135, 128–129.
Wever, S., Zillikens, D., and Brocker, E. B. (1996), Br J Dermatol 135, 862–863.
Ahmed, A.R. and Sami, N. (2002), J Am Acad Dermatol 46, 42–49.
Sami, N., Qureshi, A., and Ahmed, A.R. (2002), Eur J Dermatol 12, 174–178.
Toth, G. G. and Jonkman, M. F. (1999), Br J Dermatol 141, 583–585.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akerman, L., Mimouni, D. & David, M. Intravenous immunoglobulin for treatment of pemphigus. Clinic Rev Allerg Immunol 29, 289–294 (2005). https://doi.org/10.1385/CRIAI:29:3:289
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:29:3:289